Pulmonx (LUNG) EBIAT (2019 - 2025)
Pulmonx (LUNG) has disclosed EBIAT for 7 consecutive years, with -$14.0 million as the latest value for Q3 2025.
- Quarterly EBIAT rose 1.32% to -$14.0 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$56.8 million through Sep 2025, up 0.62% year-over-year, with the annual reading at -$56.4 million for FY2024, 7.31% up from the prior year.
- EBIAT for Q3 2025 was -$14.0 million at Pulmonx, up from -$15.2 million in the prior quarter.
- The five-year high for EBIAT was -$10.2 million in Q3 2021, with the low at -$16.2 million in Q2 2023.
- Average EBIAT over 5 years is -$14.1 million, with a median of -$14.2 million recorded in 2022.
- The sharpest move saw EBIAT plummeted 163.76% in 2021, then increased 13.31% in 2024.
- Over 5 years, EBIAT stood at -$13.0 million in 2021, then decreased by 9.82% to -$14.3 million in 2022, then increased by 2.77% to -$13.9 million in 2023, then increased by 5.13% to -$13.2 million in 2024, then dropped by 5.94% to -$14.0 million in 2025.
- According to Business Quant data, EBIAT over the past three periods came in at -$14.0 million, -$15.2 million, and -$14.4 million for Q3 2025, Q2 2025, and Q1 2025 respectively.